Vertex Pharmaceuticals and ViaCyte Inc are in the NEWS
Vertex Pharmaceuticals (VRTX) entered into a definitive agreement under which it will acquire ViaCyte, a private biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
From Vertex Pharmaceuticals and ViaCyte Inc
Reshma Kewalramani, M . . .
This content is for paid subscribers.
Today’s Highlights
July 12, 2022
